Doctors Warn: Illinois Cannabis Legalisation Has Sparked a Public Health Crisis Nobody Bargained For

When Illinois lawmakers voted in 2019 to legalise recreational cannabis, the public health risks were real and the recreational cannabis risks were known. Yet politicians pressed ahead with three key promises: they would dismantle the black market, keep health consequences minimal, and generate meaningful tax revenue. Six years on, only one of those promises has held up. The cost of that revenue is becoming impossible to ignore.

Illinois was the first state in the nation to legalise recreational cannabis through legislation rather than a public referendum. Governor JB Pritzker and a Democratic-controlled legislature made that call, not voters. What followed has exposed the complex and troubling consequences of cannabis legalisation across the United States.

The Numbers Look Good Until You Look Closer

On the surface, the financial case appears strong. Illinois recorded more than $2 billion in cannabis sales in 2024 alone, a 2.5% increase on the previous year. The state collected $490 million in tax revenue. For a governor reportedly eyeing a presidential run, these figures make for compelling campaign material.

But the balance sheet tells only part of the story.

Illinois’ fifth Annual Cannabis Report found that 7.7% of residents aged 16 to 64 now meet the criteria for a likely cannabis use disorder. That figure stood at 6.5% in 2022. Before the adult use cannabis law took effect in 2020, fewer than 2% of adults met the same criteria. A further 11.9% now fall into the category of hazardous cannabis use. People living with severe mental illness account for a disproportionately large share of that rise.

These are not abstract statistics. They represent real people whose cannabis use has moved well beyond recreational into territory that demands attention.

Cannabis Legalisation Public Health Pressures Hit Emergency Rooms Hard

The human cost of cannabis legalisation is showing up directly in Illinois hospitals. Around 10% of Illinois adults surveyed in 2024 reported cannabis-related problems serious enough to send them to a doctor or an emergency department. Just over 30% of cannabis users surveyed reported some form of adverse event.

The starkest sign is the surge in cannabinoid hyperemesis syndrome. This condition causes severe, uncontrollable vomiting after chronic cannabis use. Doctors once considered it rare. Now roughly 7% of past-year cannabis users in Illinois report symptoms consistent with the condition, generating more than 6,000 emergency room encounters in a single year.

Road safety figures are equally troubling. In 2023, 30.3% of drivers in fatal crashes who underwent testing came back positive for cannabis. That is the highest proportion among all neighbouring Midwestern states. It sits badly alongside the original promises of minimal public health risk.

The Black Market Did Not Go Away

Supporters of cannabis legalisation argued that a regulated legal market would cut off criminal supply chains. Illinois shows that has not happened.

In 2021, illegal cannabis sales in Illinois reached an estimated $2.23 billion. Legal sales that same year totalled $1.37 billion. Chicago operates as a major hub for drug trafficking across the Midwest, with local criminal networks controlling a large share of the regional retail market.

The revenue picture also has a cross-border dimension that rarely draws attention. Customers from Iowa, Wisconsin and Indiana, where cannabis remains illegal, currently account for more than one fifth of Illinois’ legal cannabis sales. Illinois profits from demand it generates in neighbouring states. Those states then deal with the health and enforcement fallout.

Recreational Cannabis Risks Were Understated From the Start

The path from medical cannabis to full recreational legalisation has long drawn scrutiny. Illinois makes for a clear case study.

The state lists more than 50 qualifying health conditions for medical cannabis. Utah recognises 16. California recognises 11. Yet in 2024, only 13% of the state’s 56.3 million individual cannabis sales served medical purposes. The remaining 87% were purely recreational.

A review published in the Journal of the American Medical Association examined 15 years of research and found that evidence remains insufficient to support cannabis or cannabinoids for most medical conditions. The health benefits were overstated. Medical cannabis, many argue, was always a precursor to recreational legalisation rather than a genuine medical programme.

A Federal Shift Adds a New Chapter

Illinois is not navigating this alone. President Donald Trump recently signed an order directing the Drug Enforcement Administration to move cannabis from Schedule I to Schedule III under the Controlled Substances Act. Schedule I covers the most tightly restricted substances. Schedule III covers those with moderate to low dependence potential.

Cannabis will stay federally illegal for recreational use. But the reclassification will ease banking restrictions and reduce the tax burden on cannabis businesses. The cannabis industry spent heavily on lobbying and political donations to reach this point.

More federal research will now follow. Whether it supports industry claims or adds to the evidence of harm is a question worth watching closely.

What Comes Next for Cannabis Legalisation and Public Health?

Few politicians are willing to push for reversing cannabis legalisation. Comparisons to Prohibition carry weight. Re-criminalising a substance with broad public support would likely create its own set of problems.

But critics of legalisation are no longer easy to dismiss as out-of-touch. Cannabis use disorder rates are climbing. Emergency departments are strained. The illegal market is thriving. Road deaths involving cannabis are rising. These are consequences that either caught policymakers off guard or were never honestly shared with the public.

The money came in, as promised. The public health risks were supposed to remain minimal.

They have not.

Dr Cory Franklin is a retired intensive care physician and author of “The COVID Diaries 2020 to 2024: Anatomy of a Contagion as It Happened.” Dr Jerrold B. Leikin is a medical toxicologist and adjunct clinical professor in the Division of Environmental and Occupational Health at the University of Illinois at Chicago. He formerly served on the Illinois Board of Health from 2016 to 2019.

By Cory Franklin and Jerrold B. Leikin Published: January 2026

Source: chicagotribune